Bär & Karrer Advises SK Capital LP on
the Acquisition of Swixx BioPharma
Holding AG

The US private equity investor SK Capital LP has acquired the Swixx BioPharma Group. The Swixx BioPharma Group is a leading global full-service partner in the distribution of biopharmaceutical products, particularly in Central and Eastern Europe and Latin America.

Bär & Karrer is acting as counsel to SK Capital LP in this transaction. The team is led by Christoph Neeracher and Philippe Seiler and also includes Therry Lehmann, Thomas Rohde, Romina Lauper, Rahel Brüschweiler, Markus Mezger, Max Winnenburg (all M&A), Susanne Schreiber, Martin Leu, and Leotrim Berisha (Tax), Markus Wang and Christine Schweikard (IP/IT), Mani Reinert, Li Wei Dutler, and Martin Werner (Competition), Christian Kunz and Katharina Cardon (Data Protection), Markus Schott, Julia Stempfel, and Jan Grossniklaus (Regulatory), Rocco Rigozzi and Patrick Neher (Real Estate), Laura Widmer and Manuel Schmid (Employment), Ralph Malacrida and Colin Giezendanner (Financing), and Mariel Hoch (Public M&A).